Trials / Completed
CompletedNCT00894439
Study Evaluating BLI-489 and Piperacillin in Healthy Subjects
A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BLI-489/Piperacillin | |
| DRUG | BLI-489 | |
| DRUG | Piperacillin |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2009-05-07
- Last updated
- 2009-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00894439. Inclusion in this directory is not an endorsement.